uniQure (NASDAQ:QURE) Price Target Raised to $20.00

uniQure (NASDAQ:QURE) had its price target lifted by equities research analysts at Mizuho from $7.00 to $20.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Mizuho’s price target suggests a potential upside of 26.90% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, December 10th. Cantor Fitzgerald increased their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Price Performance

Shares of uniQure stock opened at $15.76 on Thursday. uniQure has a 1-year low of $3.73 and a 1-year high of $17.71. The firm’s 50-day moving average price is $7.70 and its two-hundred day moving average price is $6.61. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $768.19 million, a price-to-earnings ratio of -3.18 and a beta of 0.89.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, equities analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. raised its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. Walleye Capital LLC acquired a new position in uniQure during the third quarter worth $444,000. FMR LLC raised its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in uniQure by 49.1% in the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 89,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of uniQure by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after acquiring an additional 16,464 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.